iPierian Receives $30,000,000 New Funding Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    951 Gateway Blvd South San Francisco, CA 94080
  • Company Description
    iPierian is a pioneering biopharmaceutical company that is taking the cutting-edge technologies of cellular reprogramming and directed differentiation to an entirely new level to harness the power of induced pluripotent stem cells to advance the understanding of human diseases and accelerate the discovery of more effective therapeutics for patients.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    For iPierian, proceeds of the financing will be used to accelerate the clinical development program for IPN007, a monoclonal antibody targeting the Tau protein for the treatment of Alzheimer’s disease and other tauopathies (e.g. progressive supranuclear palsy, frontotemporal dementia). iPierian selected IPN007 based on novel secreted Tau discoveries made using its induced pluripotent stem cell (iPSC) platform.
  • M&A Terms
  • Venture Investor
    SR One
  • Venture Investor
    Kleiner Perkins Caufield & Byers
  • Venture Investor
    MPM Capital
  • Venture Investor
    Google Ventures
  • Venture Investor
    Highland Capital Partners
  • Venture Investor
    Atel Ventures
  • Venture Investor
    Mitsubishi Corporation

Trending on Xconomy